Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Libtayo Approved for First-Line Treatment of Advanced Lung Cancer

April 2021 Vol 7 No 2

In February 2021, the FDA approved a new indication for Libtayo (cemiplimab; from Regeneron/sanofi-aventis), a PD-1 inhibitor, for the first-line treatment of patients with advanced or metastatic (spreading) non–small-cell lung cancer (NSCLC) who are not candidates for surgery or curative chemoradiation and whose tumors have high PD-L1 expression but no EGFR, ALK, or ROS1 mutations.

Libtayo was previously approved for the treatment of skin cancer.

This new approval was based on data from Study 1624 that included 710 patients with advanced or metastatic NSCLC who were not candidates for surgery or chemoradiation. The patients were divided into 2 groups to receive either intravenous Libtayo every 3 weeks for 108 weeks or platinum-based chemotherapy.

The average overall survival was 22.1 months with Libtayo versus 14.3 months with chemotherapy. The average time without disease progression was 6.2 months with Libtayo versus 5.6 months with chemotherapy. The overall response rate was 37% with Libtayo and 21% with chemotherapy.

The most common side effects with Libtayo in this study were musculoskeletal pain, rash, anemia, fatigue, decreased appetite, pneumonia, and cough.

Recommended For You